A continuous time Markov model adequately described efavirenz treatment-associated neuropsychiatric impairment.
Efavirenz dose reduction from 600 to 400 mg would reduce the duration of neuropsychiatric impairment in HIV patients who get impaired without affecting efficacy.
Delayed neuropsychiatric symptoms are less likely related to efavirenz exposure.